Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

Official title

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

Overview

This Phase 3 study will be conducted in different countries around the world with up to about 544 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with available standard of care therapy that is already approved and used for ovarian cancer. Participants will receive either Rina-S monotherapy (by itself), Rina-S plus bevacizumab, bevacizumab (standard of care) by itself, or no treatment (only monitoring, also standard of care). No participants will be given placebo. Participants will participate in 1 of 2 arms. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participants will be asked to attend 1 to 3 visits at the study clinic for each cycle (duration of cycle is 3 weeks). During visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity and imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) for each participant will be different for every participant.

Detailed description

This is a randomized, open-label, Phase 3 study of Rina-S + standard of care (SOC) versus SOC as maintenance treatment after second-line (2L) platinum-based doublet chemotherapy in participants with recurrent PSOC.

Interventions

• Drug Rina-S
  Intravenous (IV) infusion
• Drug Bevacizumab
  IV infusion

Primary outcome measures

• Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1, as Determined by Blinded Independent Central Review (BICR) [Time frame: Up to approximately 3 years]

Secondary outcome measures (6)

• Overall Survival [Time frame: Up to approximately 4 years]
• PFS, per RECIST 1.1, as Determined by Investigator Assessment [Time frame: Up to approximately 3 years]
• Second Determination of PFS (PFS2) [Time frame: Up to approximately 4 years]
• Number of Participants with Treatment-emergent Adverse Events (TEAEs) [Time frame: Up to approximately 4 years]
• Overall Change from Baseline in Global Health Status (GHS)/Quality of Life (QoL) Score Using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) Questionnaire [Time frame: Up to approximately 4 years]
• Time to Deterioration (TTD) in the GHS/QoL Score Using the QLQ-C30 [Time frame: Up to approximately 4 years]

Eligibility criteria

Inclusion criteria

• Must have histologically or cytologically confirmed high-grade serous or endometrioid epithelial ovarian cancer (EOC), primary peritoneal cancer, or fallopian tube cancer.
• Must have PSOC defined as progressive disease > 6 months (ie, 183 days) from the last dose of primary (first-line \[1L\]) platinum therapy.
• Participants with known breast cancer (BRCA)-mutated (somatic or germline) or homologous recombination deficiency (HRD)-positive ovarian cancer who achieved complete response (CR)/no clinical evidence of disease (NED) or partial response (PR) following 1L platinum-based chemotherapy regimen must have previously received PARPi maintenance therapy as part of their 1L treatment.
• Must have completed platinum-based chemotherapy in the 2L treatment for recurrent PSOC.
• Must be randomized no later than 8 weeks from the last dose of the 2L platinum-based therapy.
• Participants must have achieved a CR/NED, PR; or SD permitted only if bevacizumab was given in 2L in combination with platinum-based chemotherapy, as assessed by the investigator, following completion of 2L platinum-based chemotherapy.

Exclusion criteria

• Participants with clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, or low-grade/borderline ovarian tumors
• More than 2 prior lines of systemic therapy.
• Progression while on or following 2L platinum-based regimen prior to randomization.
• Participants who receive an intervening systemic anticancer treatment (excluding bevacizumab) after the last dose of 2L platinum-based chemotherapy and prior to randomization.

Note: Other protocol-defined Inclusion and Exclusion criteria may apply.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

Japan · 12 centers

• National Hospital Organization Hokkaido Cancer Center — Sapporo
• Sapporo Medical University Hospital — Sapporo
• Hyogo Cancer Center — Akashi
• Mie University Graduate School Of Medicine — Tsu
• Osaka Medical and Pharmaceutical University Hospital — Takatsuki
• Saitama Medical University International Medical Center — Hidaka
• The Jikei University Kashiwa Hospital — Kashiwa
• Niigata University Medical & Dental Hospital — Niigata
• … and 4 more centers

United States · 4 centers

• Mt. Sinai Comprehensive Cancer Center — Miami
• Sarasota Memorial Health Care System — Sarasota
• Miami Valley Hospital South — Centerville
• Zangmeister Cancer Center — Columbus

Identifiers

NCT: NCT07225270 · GCT1184-04 · 2025-522167-15-00 · jRCT2051250197 · GOG-3134 · ENGOT-OV96

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗